背部疼痛综合征局部治疗的新可能性

Надежда Александровна Шостак, А. А. Клименко, Д. Ю. Андрияшкина
{"title":"背部疼痛综合征局部治疗的新可能性","authors":"Надежда Александровна Шостак, А. А. Клименко, Д. Ю. Андрияшкина","doi":"10.17650/1818-8338-2017-11-2-74-79","DOIUrl":null,"url":null,"abstract":"Purpose of study – to examine effectiveness and tolerability of therapy рatch NANOPLAST forte in comparison with “placebo” patch in patients with back pain syndrome in conditions of prospective comparative randomized study, approved by the local ethics committee. Materials and methods. The study included 60 patients with acute/ recrudescence of chronic primary back pain syndrome, there were 30 patients in each group, which were comparable in main clinical parameters. A primary effectiveness criterion was reduction of back pain syndrome intensity at rest and during movements by no less than 50% from initial level according to visual analogue scale (mm). Overall effectiveness of NANOPLAST forte patch was evaluated separately by doctor and patient on the 10th day according to the following grading: significant improvement; improvement; absence of effect. A need for administration of non-steroidal anti-inflammatory drugs (NSAID) was assessed during the study. A patch was applied once a day for 12 h (from 9 to 21 h). Tolerability of NANOPLAST forte patch and “Placebo” patch was evaluated according to frequency and severity of local and/or systemic adverse events, and to tolerability grading: very good effect, good effect, satisfactory effect, absence of effect. Frequency of achievement of not less than 50% of back pain reduction at rest was significantly higher in NANOPLAST forte group than in “placebo” group (96,6% versus 23.3% respectively; р=0.001, Pearson’s chi-squared test), as well as during movements (93,3% versus 40% respectively; р=0.001, Pearson’s chi-squared test). Evaluation of treatment effectiveness was higher in NANOPLAST forte group in comparison with “Placebo” group in the opinion of both patient and doctor. Pain intensity during walking and at rest statistically significantly decreased according to visual analogue scale (p<0.05, Wilcoxon test) by the 10th day  in NANOPLAST forte group. A need for additional administration of non-steroidal anti-inflammatory drugs was statistically significantly lower in NANOPLAST forte group in comparison with “Placebo” group (р<0.05, Pearson’s chi-squared test). All patients completed the study. Adverse events related to use of NANOPLAST forte patch were not detected. Conclusion. NANOPLAST forte can be recommended as an effective and safe method of local therapy in case of back pains.","PeriodicalId":30685,"journal":{"name":"Klinicist","volume":"11 1","pages":"74-79"},"PeriodicalIF":0.0000,"publicationDate":"2017-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"НОВЫЕ ВОЗМОЖНОСТИ ЛОКАЛЬНОЙ ТЕРАПИИ БОЛЕВОГО СИНДРОМА В СПИНЕ\",\"authors\":\"Надежда Александровна Шостак, А. А. Клименко, Д. Ю. Андрияшкина\",\"doi\":\"10.17650/1818-8338-2017-11-2-74-79\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose of study – to examine effectiveness and tolerability of therapy рatch NANOPLAST forte in comparison with “placebo” patch in patients with back pain syndrome in conditions of prospective comparative randomized study, approved by the local ethics committee. Materials and methods. The study included 60 patients with acute/ recrudescence of chronic primary back pain syndrome, there were 30 patients in each group, which were comparable in main clinical parameters. A primary effectiveness criterion was reduction of back pain syndrome intensity at rest and during movements by no less than 50% from initial level according to visual analogue scale (mm). Overall effectiveness of NANOPLAST forte patch was evaluated separately by doctor and patient on the 10th day according to the following grading: significant improvement; improvement; absence of effect. A need for administration of non-steroidal anti-inflammatory drugs (NSAID) was assessed during the study. A patch was applied once a day for 12 h (from 9 to 21 h). Tolerability of NANOPLAST forte patch and “Placebo” patch was evaluated according to frequency and severity of local and/or systemic adverse events, and to tolerability grading: very good effect, good effect, satisfactory effect, absence of effect. Frequency of achievement of not less than 50% of back pain reduction at rest was significantly higher in NANOPLAST forte group than in “placebo” group (96,6% versus 23.3% respectively; р=0.001, Pearson’s chi-squared test), as well as during movements (93,3% versus 40% respectively; р=0.001, Pearson’s chi-squared test). Evaluation of treatment effectiveness was higher in NANOPLAST forte group in comparison with “Placebo” group in the opinion of both patient and doctor. Pain intensity during walking and at rest statistically significantly decreased according to visual analogue scale (p<0.05, Wilcoxon test) by the 10th day  in NANOPLAST forte group. A need for additional administration of non-steroidal anti-inflammatory drugs was statistically significantly lower in NANOPLAST forte group in comparison with “Placebo” group (р<0.05, Pearson’s chi-squared test). All patients completed the study. Adverse events related to use of NANOPLAST forte patch were not detected. Conclusion. NANOPLAST forte can be recommended as an effective and safe method of local therapy in case of back pains.\",\"PeriodicalId\":30685,\"journal\":{\"name\":\"Klinicist\",\"volume\":\"11 1\",\"pages\":\"74-79\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-12-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Klinicist\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17650/1818-8338-2017-11-2-74-79\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinicist","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1818-8338-2017-11-2-74-79","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

研究目的——在经当地伦理委员会批准的前瞻性比较随机研究条件下,检查与“安慰剂”贴片相比,NANOPLAST特强治疗背痛综合征患者的有效性和耐受性。材料和方法。该研究包括60例慢性原发性背痛综合征急性/复发患者,每组30例,主要临床参数具有可比性。一个主要的有效性标准是根据视觉模拟量表(mm),在休息和运动过程中,背痛综合征强度从初始水平降低不少于50%。第10天,医生和患者分别根据以下分级对NANOPLAST forte贴片的总体有效性进行评估:显著改善;改善无效。研究期间评估了非甾体抗炎药(NSAID)的给药需求。每天施用一次贴片,持续12小时(从9到21小时)。根据局部和/或全身不良事件的频率和严重程度,以及耐受性分级:非常好的效果、良好的效果、满意的效果、无效果,评估NANOPLAST forte贴剂和“安慰剂”贴剂的耐受性。NANOPLAST forte组在休息时实现不低于50%的背痛减轻的频率显著高于“安慰剂”组(分别为96.6%和23.3%;р=0.001,Pearson卡方检验),以及在运动过程中(分别为93.3%和40%;р=0.001,Pearson'sχ2检验)。患者和医生认为,与“安慰剂”组相比,NANOPLAST特强组的治疗效果评价更高。根据视觉模拟量表(p<0.05,Wilcoxon检验),到第10天,NANOPLAST特强组行走和休息时的疼痛强度在统计学上显著降低。与“安慰剂”组相比,NANOPLAST forte组额外服用非甾体抗炎药的需求在统计学上显著降低(р<0.05,Pearson卡方检验)。所有患者均完成了研究。未发现与使用NANOPLAST特强贴剂有关的不良事件。结论在背痛的情况下,NANOPLAST forte可以被推荐为一种有效且安全的局部治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
НОВЫЕ ВОЗМОЖНОСТИ ЛОКАЛЬНОЙ ТЕРАПИИ БОЛЕВОГО СИНДРОМА В СПИНЕ
Purpose of study – to examine effectiveness and tolerability of therapy рatch NANOPLAST forte in comparison with “placebo” patch in patients with back pain syndrome in conditions of prospective comparative randomized study, approved by the local ethics committee. Materials and methods. The study included 60 patients with acute/ recrudescence of chronic primary back pain syndrome, there were 30 patients in each group, which were comparable in main clinical parameters. A primary effectiveness criterion was reduction of back pain syndrome intensity at rest and during movements by no less than 50% from initial level according to visual analogue scale (mm). Overall effectiveness of NANOPLAST forte patch was evaluated separately by doctor and patient on the 10th day according to the following grading: significant improvement; improvement; absence of effect. A need for administration of non-steroidal anti-inflammatory drugs (NSAID) was assessed during the study. A patch was applied once a day for 12 h (from 9 to 21 h). Tolerability of NANOPLAST forte patch and “Placebo” patch was evaluated according to frequency and severity of local and/or systemic adverse events, and to tolerability grading: very good effect, good effect, satisfactory effect, absence of effect. Frequency of achievement of not less than 50% of back pain reduction at rest was significantly higher in NANOPLAST forte group than in “placebo” group (96,6% versus 23.3% respectively; р=0.001, Pearson’s chi-squared test), as well as during movements (93,3% versus 40% respectively; р=0.001, Pearson’s chi-squared test). Evaluation of treatment effectiveness was higher in NANOPLAST forte group in comparison with “Placebo” group in the opinion of both patient and doctor. Pain intensity during walking and at rest statistically significantly decreased according to visual analogue scale (p<0.05, Wilcoxon test) by the 10th day  in NANOPLAST forte group. A need for additional administration of non-steroidal anti-inflammatory drugs was statistically significantly lower in NANOPLAST forte group in comparison with “Placebo” group (р<0.05, Pearson’s chi-squared test). All patients completed the study. Adverse events related to use of NANOPLAST forte patch were not detected. Conclusion. NANOPLAST forte can be recommended as an effective and safe method of local therapy in case of back pains.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
15
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信